Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics.
Apomorphine challenge tests (0.5 mg SC) were performed in 14 normal male volunteers and in 9 male schizophrenic inpatients, drug-free for at least 2 wk. In the normal volunteers, apomorphine induced an increase of serum growth hormone (GH) (maximum at 40 min), of vasopressin-neurophysin (hNpI) (maximum at 20 min), and oxytocin-neurophysin (hNpII) (maximum at 20 min). The release of neurophysins was independent of digestive side effects. In the schizophrenics, the GH level and release pattern were similar to those in the controls. The basal level of hNpI was reduced (t0: 0.42 +/- 0.1 ng/ml in the schizophrenics and 0.66 +/- 0.05 ng/ml in the controls, p < 0.02). In contrast, the basal level of hNpII was increased (3.34 +/- 0.04 ng/ml in the schizophrenics to 0.92 +/- 0.21 ng/ml in the controls, p = 0.001). The response to apomorphine was blunted, with no significant release of hNpI or of hNpII. Although the hNpII data are consistent with an increased dopaminergic tone, the psychopathological meaning of the increased basal oxytocinergic and decreased vasopressinergic functions remains to be defined.
Legros
J J
JJ
Neuroendocrine Unit, University of Liége, Belgium.
Gazzotti
C
C
Carvelli
T
T
Franchimont
P
P
Timsit-Berthier
M
M
von Frenckell
R
R
Ansseau
M
M
D000328:Adult; D001058:Apomorphine; D001127:Arginine Vasopressin / Q000097:blood*; D004298:Dopamine / Q000502:physiology*; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D009481:Neurophysins / Q000097:blood*; D010121:Oxytocin / Q000097:blood*; D010904:Pituitary Gland, Posterior / Q000503:physiopathology; D012016:Reference Values; D012559:Schizophrenia / Q000503:physiopathology*; D012565:Schizophrenic Psychology
D009481:Neurophysins; D001127:Arginine Vasopressin; D010121:Oxytocin; D013006:Growth Hormone; D001058:Apomorphine; D004298:Dopamine